KNSA
Kiniksa's Robust Growth and Milestones Dominate Q1 2026 Results
In its latest conference call, Kiniksa, a biopharmaceutical company focused on developing therapies for rare diseases, showcased impressive growth in the first quarter of 2026. The company's CEO, Sanj K. Patel, highlighted the significant commercial progress made with ARCALYST, as well as advancements in their pipeline programs. As